Switch theme
Sign up to access all valuation multiples
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
2000
2.0K+
LTM Revenue $203M
LTM EBITDA $38.2M
$379M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Duopharma Biotech has a last 12-month revenue (LTM) of $203M and a last 12-month EBITDA of $38.2M.
In the most recent fiscal year, Duopharma Biotech achieved revenue of $192M and an EBITDA of $35.7M.
Duopharma Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Duopharma Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $203M | XXX | $192M | XXX | XXX | XXX |
| Gross Profit | $203M | XXX | $71.2M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 37% | XXX | XXX | XXX |
| EBITDA | $38.2M | XXX | $35.7M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBIT | $27.4M | XXX | $23.4M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $17.7M | XXX | $14.8M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $58.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Duopharma Biotech's stock price is MYR 1 (or $0).
Duopharma Biotech has current market cap of MYR 1.4B (or $322M), and EV of MYR 1.6B (or $379M).
See Duopharma Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $379M | $322M | XXX | XXX | XXX | XXX | $0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Duopharma Biotech has market cap of $322M and EV of $379M.
Duopharma Biotech's trades at 2.0x EV/Revenue multiple, and 10.6x EV/EBITDA.
Equity research analysts estimate Duopharma Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Duopharma Biotech has a P/E ratio of 18.2x.
See valuation multiples for Duopharma Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $322M | XXX | $322M | XXX | XXX | XXX |
| EV (current) | $379M | XXX | $379M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 9.9x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBIT | 13.8x | XXX | 16.2x | XXX | XXX | XXX |
| EV/Gross Profit | 1.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.2x | XXX | 21.8x | XXX | XXX | XXX |
| EV/FCF | 92.1x | XXX | 32.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDuopharma Biotech's last 12 month revenue growth is 11%
Duopharma Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $24K for the same period.
Duopharma Biotech's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Duopharma Biotech's rule of X is 46% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Duopharma Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 22% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $24K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Duopharma Biotech acquired XXX companies to date.
Last acquisition by Duopharma Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Duopharma Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Duopharma Biotech founded? | Duopharma Biotech was founded in 2000. |
| Where is Duopharma Biotech headquartered? | Duopharma Biotech is headquartered in Malaysia. |
| How many employees does Duopharma Biotech have? | As of today, Duopharma Biotech has 2.0K+ employees. |
| Is Duopharma Biotech publicy listed? | Yes, Duopharma Biotech is a public company listed on KLS. |
| What is the stock symbol of Duopharma Biotech? | Duopharma Biotech trades under 7148 ticker. |
| When did Duopharma Biotech go public? | Duopharma Biotech went public in 2002. |
| Who are competitors of Duopharma Biotech? | Similar companies to Duopharma Biotech include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Duopharma Biotech? | Duopharma Biotech's current market cap is $322M |
| What is the current revenue of Duopharma Biotech? | Duopharma Biotech's last 12 months revenue is $203M. |
| What is the current revenue growth of Duopharma Biotech? | Duopharma Biotech revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Duopharma Biotech? | Current revenue multiple of Duopharma Biotech is 1.9x. |
| Is Duopharma Biotech profitable? | Yes, Duopharma Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Duopharma Biotech? | Duopharma Biotech's last 12 months EBITDA is $38.2M. |
| What is Duopharma Biotech's EBITDA margin? | Duopharma Biotech's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Duopharma Biotech? | Current EBITDA multiple of Duopharma Biotech is 9.9x. |
| What is the current FCF of Duopharma Biotech? | Duopharma Biotech's last 12 months FCF is $4.1M. |
| What is Duopharma Biotech's FCF margin? | Duopharma Biotech's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Duopharma Biotech? | Current FCF multiple of Duopharma Biotech is 92.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
